A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar

Immunotherapy, Ahead of Print.

Source: Immunotherapy - May 11, 2022 Category: Allergy & Immunology Authors: Patrick Cobb Dietger Niederwieser Stanley Cohen Caroline Hamm Gerd Burmester Neungseon Seo Sonya G Lehto Vladimir Hanes Source Type: research